Barbara Andraka-Christou1,2, M H Clark3, Danielle N Atkins1, Brandon Del Pozo4. 1. Department of Health Management and Informatics, University of Central Florida, Orlando, FL, USA. 2. Department of Internal Medicine (Joint Secondary Appointment), University of Central Florida, Orlando, FL, USA. 3. Department of Learning Sciences and Educational Research, University of Central Florida, Orlando, FL, USA. 4. Warren Alpert Medical School, Brown University, Providence, RI, USA.
Abstract
Background: Criminal problem-solving courts and civil dependency courts often have participants with substance use disorder (SUD), including opioid use disorder (OUD). These courts refer participants to treatment and set treatment-related requirements for court participants to avoid incarceration or to regain custody of children. Medications for opioid use disorder (MOUD) are the most effective treatment for OUD but are underutilized by court system participants. Little is known about variation in court policies for different MOUDs. Also, more information is needed about types of policies for each MOUD, including whether participants may begin MOUD, continue previously begun MOUD, or complete the court program with MOUD. Methods: An online survey was distributed to criminal problem-solving and civil dependency judges in Florida in 2019 and 2020, yielding data from 58 judges (a 24% response rate). We used nonparametric statistics to test hypotheses with ordinal data. A Friedman's test for related samples or Cochran's Q was used to make within-group comparisons between policies and MOUDs. Results: We found considerable policy variation, with more permissive policies for naltrexone than buprenorphine or methadone, and more permissive policies for continuing MOUD than for initiating MOUD or completing a court program with MOUD. For each medication, less than one quarter of judges indicated their court always permits MOUD, with most indicating that MOUD is permitted sometimes or usually. Conclusion: Because respondents rarely chose "never" or "always" for any MOUD policy, most courts appear to be making MOUD decisions on a case-by-case basis. A clearer understanding of this decision-making process is needed. Some court participants may be required to discontinue MOUD before completing a court program, even if they were permitted to start or continue MOUD treatment. Discontinuation of MOUD without medical justification is contrary to the standard of care for individuals with OUD and increases their risk of overdose.
Background: Criminal problem-solving courts and civil dependency courts often have participants with substance use disorder (SUD), including opioid use disorder (OUD). These courts refer participants to treatment and set treatment-related requirements for court participants to avoid incarceration or to regain custody of children. Medications for opioid use disorder (MOUD) are the most effective treatment for OUD but are underutilized by court system participants. Little is known about variation in court policies for different MOUDs. Also, more information is needed about types of policies for each MOUD, including whether participants may begin MOUD, continue previously begun MOUD, or complete the court program with MOUD. Methods: An online survey was distributed to criminal problem-solving and civil dependency judges in Florida in 2019 and 2020, yielding data from 58 judges (a 24% response rate). We used nonparametric statistics to test hypotheses with ordinal data. A Friedman's test for related samples or Cochran's Q was used to make within-group comparisons between policies and MOUDs. Results: We found considerable policy variation, with more permissive policies for naltrexone than buprenorphine or methadone, and more permissive policies for continuing MOUD than for initiating MOUD or completing a court program with MOUD. For each medication, less than one quarter of judges indicated their court always permits MOUD, with most indicating that MOUD is permitted sometimes or usually. Conclusion: Because respondents rarely chose "never" or "always" for any MOUD policy, most courts appear to be making MOUD decisions on a case-by-case basis. A clearer understanding of this decision-making process is needed. Some court participants may be required to discontinue MOUD before completing a court program, even if they were permitted to start or continue MOUD treatment. Discontinuation of MOUD without medical justification is contrary to the standard of care for individuals with OUD and increases their risk of overdose.
Authors: Wei-Hsuan Lo-Ciganic; Julie M Donohue; Joo Yeon Kim; Elizabeth E Krans; Bobby L Jones; David Kelley; Alton E James; Marian P Jarlenski Journal: Pharmacoepidemiol Drug Saf Date: 2018-09-07 Impact factor: 2.890
Authors: Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi Journal: JAMA Netw Open Date: 2020-02-05
Authors: Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling Journal: J Stud Alcohol Drugs Date: 2013-07 Impact factor: 2.582
Authors: David A Fiellin; Brent A Moore; Lynn E Sullivan; William C Becker; Michael V Pantalon; Marek C Chawarski; Declan T Barry; Patrick G O'Connor; Richard S Schottenfeld Journal: Am J Addict Date: 2008 Mar-Apr
Authors: Barbara Andraka-Christou; Olivia Randall-Kosich; Matthew Golan; Rachel Totaram; Brendan Saloner; Adam J Gordon; Bradley D Stein Journal: Health Justice Date: 2022-03-31
Authors: Fatema Z Ahmed; Barbara Andraka-Christou; M H Clark; Rachel Totaram; Danielle N Atkins; Brandon Del Pozo Journal: Health Justice Date: 2022-07-27